Natera Fights Illumina's Bid To Invalidate DNA Testing Patent

Law360 (September 16, 2020, 10:36 PM EDT) -- Natera Inc. pushed back Wednesday against Illumina Inc.'s assertions that Natera's patent covering fetal DNA testing technology for detecting Down syndrome was invalid in light of the prior art, contending that Illumina raised an argument during the remote hearing before the Patent Trial and Appeal Board that wasn't in its petition.

Natera told the board that an argument Illumina made during the hearing that the claimed invention requires a pure fetal DNA sample isolated from maternal blood wasn't made in Illumina's petition. Because the petition relied on an argument concerning a mixture of fetal and maternal DNA, Natera attorney Elizabeth Laughton...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!